The value of plasma fibrillin-1 level in patients with spontaneous cerebral artery dissection
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To explore the value of plasma fibrillin-1 levels in patients with spontaneous cerebral artery dissection (sCeAD).
Methods A single-center prospective cohort of 99 consecutive patients with sCeAD between February 2013 and December 2015 were age and sex matched with 115 patients with non-sCeAD ischemic stroke and 20 healthy participants undergoing routine physical examination. The plasma fibrillin-1 level was measured with ELISA and compared among the 3 groups. The associations of fibrillin-1 with site, acuity, and severity of dissection, as well as clinical and radiographic prognosis of patients, were analyzed.
Results One hundred nine plasma samples from 99 patients with sCeAD, 115 from disease control patients, and 20 from healthy participants were collected. The plasma fibrillin-1 level of the dissection group (mean 85.56 ng/mL [95% confidence interval 81.53–89.59]) was higher than that of non-sCeAD ischemic stroke group (77.13 ng/mL [73.64–80.63], p = 0.015) or healthy controls (73.04 ng/mL [65.94–80.13], p = 0.029). Such differences were most prominent in the acute stage (97.64 ng/mL [91.64–103.64], 74.39 ng/mL [68.95–79.84], and 73.04 ng/mL [65.95–80.13], respectively). A cutoff value of 88.455 ng/mL was determined to differentiate acute dissection from nondissection stroke with a sensitivity of 0.778 and a specificity of 0.800. Higher fibrillin-1 level was detected in patients with more severe dissection radiographically (p < 0.001), while patients with lower fibrillin-1 concentration at baseline achieved better morphologic recovery on follow-up imaging tests (p = 0.003).
Conclusion Plasma fibrillin-1 is a promising biomarker for aiding the diagnosis of acute sCeAD and may have potential value in lesion severity grading and radiographic prognosis prediction.
Classification of evidence This study provides Class III evidence that patients with sCeAD have significantly higher levels of plasma fibrillin-1 than patients with ischemic stroke attributable to a cause other than sCeAD.
Glossary
- CI=
- confidence interval;
- NIHSS=
- NIH Stroke Scale;
- sCeAD=
- spontaneous cerebral artery dissection
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Class of Evidence: NPub.org/coe
Editorial, page 399
- Received June 20, 2017.
- Accepted in final form October 22, 2017.
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Differential features of carotid and vertebral artery dissectionsThe CADISP StudyS. Debette, C. Grond-Ginsbach, M. Bodenant et al.Neurology, September 07, 2011 -
Articles
Outcomes and prognostic factors of intracranial unruptured vertebrobasilar artery dissectionB.M. Kim, S.H. Kim, D.I. Kim et al.Neurology, May 16, 2011 -
Article
Outcomes after ischemic stroke caused by intracranial atherosclerosis vs dissectionJaewon Shin, Jong-Won Chung, Moo Seok Park et al.Neurology, October 05, 2018 -
Article
Artery occlusion independently predicts unfavorable outcome in cervical artery dissectionChristopher Traenka, Caspar Grond-Ginsbach, Barbara Goeggel Simonetti et al.Neurology, November 22, 2019